Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

neogen corp. - NEOG

NEOG

Close Chg Chg %
6.85 0.12 1.68%

Open Market

6.97

+0.12 (1.68%)

Volume: 1.61M

Last Updated:

Dec 16, 2025, 1:13 PM EDT

Trade Now

Company Overview: neogen corp. - NEOG

NEOG Key Data

Open

$6.83

 Day Range

6.74 - 7.18

52 Week Range

3.87 - 13.41

 Market Cap

$1.49B

Shares Outstanding

217.30M

 Public Float

215.53M

Beta

1.98

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.81

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

4.32M

  

NEOG Performance

1 Week
 
 -0.15%
 
1 Month
 
 7.20%
 
3 Months
 
 22.10%
 
1 Year
 
 -43.11%
 
5 Years
 
 -83.04%
 

NEOG Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About neogen corp. - NEOG

Neogen Corp. engages in the provision of development, manufacture, and marketing of food and animal safety products. It operates through the Food Safety and Animal Safety segments. The Food Safety segment consists of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, drug residues, and levels of general sanitation. The Animal Safety segment includes a line of consumable products marketed to veterinarians and animal health product distributors. The company was founded on June 30, 1981 and is headquartered in Lansing, MI.

NEOG At a Glance

Neogen Corp.
620 Lesher Place
Lansing, Michigan 48912
Phone 1-800-232-5333 Revenue 894.66M
Industry Medical Specialties Net Income -1,092,044,000.00
Sector Health Technology Employees 2,974
Fiscal Year-end 05 / 2026
View SEC Filings

NEOG Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.421
Price to Book Ratio 0.614
Price to Cash Flow Ratio 22.61
Enterprise Value to EBITDA 15.209
Enterprise Value to Sales 2.297
Total Debt to Enterprise Value 0.444

NEOG Efficiency

Revenue/Employee 300,827.505
Income Per Employee -367,197.041
Receivables Turnover 5.833
Total Asset Turnover 0.222

NEOG Liquidity

Current Ratio 3.316
Quick Ratio 2.219
Cash Ratio 0.741

NEOG Profitability

Gross Margin 47.099
Operating Margin 1.053
Pretax Margin -126.652
Net Margin -122.062
Return on Assets -27.066
Return on Equity -41.878
Return on Total Capital -36.598
Return on Invested Capital -31.193

NEOG Capital Structure

Total Debt to Total Equity 44.061
Total Debt to Total Capital 30.585
Total Debt to Total Assets 26.184
Long-Term Debt to Equity 42.857
Long-Term Debt to Total Capital 29.749
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Neogen Corp. - NEOG

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
527.16M 822.45M 924.22M 894.66M
Sales Growth
+12.53% +56.01% +12.37% -3.20%
Cost of Goods Sold (COGS) incl D&A
284.15M 416.49M 461.59M 473.29M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
23.69M 88.38M 121.23M 125.67M
Depreciation
14.09M 17.29M 26.28M 31.75M
Amortization of Intangibles
9.60M 71.08M 94.95M 93.92M
COGS Growth
+12.13% +46.58% +10.83% +2.53%
Gross Income
243.01M 405.95M 462.63M 421.38M
Gross Income Growth
+13.00% +67.05% +13.96% -8.92%
Gross Profit Margin
+46.10% +49.36% +50.06% +47.10%
2022 2023 2024 2025 5-year trend
SG&A Expense
184.40M 368.44M 385.21M 411.96M
Research & Development
17.05M 26.04M 22.48M 21.09M
Other SG&A
167.35M 342.40M 362.73M 390.87M
SGA Growth
+30.88% +99.81% +4.55% +6.94%
Other Operating Expense
- - - -
-
Unusual Expense
(220.00K) (300.00K) 18.54M 1.07B
EBIT after Unusual Expense
58.84M 37.81M 58.89M (1.06B)
Non Operating Income/Expense
1.37M (3.90M) 2.48M (975.00K)
Non-Operating Interest Income
1.27M 3.17M 6.36M 3.11M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 55.96M 75.67M 69.68M
Interest Expense Growth
- - +35.23% -7.92%
-
Gross Interest Expense
- 55.96M 75.67M 69.68M
Interest Capitalized
- - - -
-
Pretax Income
60.21M (22.04M) (14.30M) (1.13B)
Pretax Income Growth
-20.01% -136.61% +35.10% -7,821.08%
Pretax Margin
+11.42% -2.68% -1.55% -126.65%
Income Tax
11.90M 828.00K (4.88M) (41.07M)
Income Tax - Current - Domestic
10.99M 10.57M 10.19M 1.61M
Income Tax - Current - Foreign
5.14M 9.49M 14.41M 14.09M
Income Tax - Deferred - Domestic
(4.08M) (19.27M) (27.34M) (41.07M)
Income Tax - Deferred - Foreign
(151.00K) 41.00K (2.15M) (15.69M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
48.31M (22.87M) (9.42M) (1.09B)
Minority Interest Expense
- - - -
-
Net Income
48.31M (22.87M) (9.42M) (1.09B)
Net Income Growth
-20.65% -147.34% +58.81% -11,491.59%
Net Margin Growth
+9.16% -2.78% -1.02% -122.06%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
48.31M (22.87M) (9.42M) (1.09B)
Preferred Dividends
- - - -
-
Net Income Available to Common
48.31M (22.87M) (9.42M) (1.09B)
EPS (Basic)
0.4486 -0.1211 -0.0435 -5.0349
EPS (Basic) Growth
-21.53% -127.00% +64.08% -11,474.48%
Basic Shares Outstanding
107.68M 188.88M 216.48M 216.89M
EPS (Diluted)
0.4472 -0.1211 -0.0435 -5.0349
EPS (Diluted) Growth
-21.32% -127.08% +64.08% -11,474.48%
Diluted Shares Outstanding
108.02M 188.88M 216.48M 216.89M
EBITDA
82.31M 125.89M 198.65M 135.09M
EBITDA Growth
-13.55% +52.94% +57.80% -32.00%
EBITDA Margin
+15.61% +15.31% +21.49% +15.10%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 7.625
Number of Ratings 5 Current Quarters Estimate 0.073
FY Report Date 02 / 2026 Current Year's Estimate 0.24
Last Quarter’s Earnings 0.055 Median PE on CY Estimate N/A
Year Ago Earnings -5.03 Next Fiscal Year Estimate 0.34
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 3 4
Mean Estimate 0.07 0.09 0.24 0.34
High Estimates 0.08 0.10 0.25 0.41
Low Estimate 0.06 0.07 0.22 0.28
Coefficient of Variance 13.21 15.19 7.22 16.81

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 1 1
OVERWEIGHT 0 0 0
HOLD 3 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Hold Hold

Insider Actions for Neogen Corp. - NEOG

Date Name Shares Transaction Value
Oct 29, 2025 Amy M. Rocklin Chief Legal Officer 59,325 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 367,221.75
Oct 29, 2025 David H. Naemura Chief Financial Officer 15,504 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 29, 2025 David H. Naemura Chief Financial Officer 81,024 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 501,538.56
Oct 29, 2025 David H. Naemura Chief Financial Officer 85,285 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 527,914.15
Oct 29, 2025 Amy M. Rocklin Chief Legal Officer 57,240 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 354,315.60
Oct 29, 2025 Amy M. Rocklin Chief Legal Officer 9,474 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 28, 2025 Jeffrey D. Capello Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Catherine E. Woteki Director 35,084 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 212,959.88
Oct 28, 2025 Catherine E. Woteki Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Andrea F. Wainer Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Andrea F. Wainer Director 19,769 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 119,997.83
Oct 28, 2025 Ronald D. Green Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Ronald D. Green Director 34,621 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 210,149.47
Oct 28, 2025 Raphael A. Rodriguez Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Raphael A. Rodriguez Director 36,788 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 223,303.16
Oct 28, 2025 Thierry L. Bernard Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Thierry L. Bernard Director 19,769 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 119,997.83
Oct 28, 2025 James C. Borel Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 James C. Borel Director 112,314 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 681,745.98
Oct 28, 2025 Jeffrey D. Capello Director 48,469 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 294,206.83

Neogen Corp. in the News